Ames dwarf (Prop1df/Prop1df) mice display increased sensitivity of the major GH-signaling pathways in liver and skeletal muscle

Growth Hormone and IGF Research

Volumn 20, Issue 2, 2010, Pages 118-126

  Miquet, Johanna G ^a   Muñoz, Marina C ^a   Giani, Jorge F ^a   González, Lorena ^a   Dominici, Fernando P ^a   Bartke, Andrzej ^b   Turyn, Daniel ^a   Sotelo, Ana I ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Akt; Ames dwarf mice; Erk; GH; GH signal transduction; STAT

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; JANUS KINASE 2; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PROPHET OF PITUITARY FACTOR 1; PROTEIN KINASE B; SERINE; STAT3 PROTEIN; STAT5 PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENOTYPE; GROWTH HORMONE DEFICIENCY; HORMONE ACTION; HORMONE RELEASE; HORMONE SENSITIVITY; IMMUNOBLOTTING; LIVER; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

ANIMALS; DRUG RESISTANCE; DWARFISM, PITUITARY; GLYCOGEN SYNTHASE KINASE 3; GROWTH HORMONE; HOMEODOMAIN PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER; MICE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUSCLE, SKELETAL; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, SOMATOTROPIN; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR;

EID: 77949653517     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2009.11.003     Document Type: Article

References (50)

1. Lanning N.J., Carter-Su C. Recent advances in growth hormone signaling. Rev. Endocr. Metab. Disord. 2007, 7:225-235.
2. Lichanska A.M., Waters M.J. New insights into growth hormone receptor function and clinical implications. Horm. Res. 2008, 69:138-145.
3. Liang L., Jiang J., Frank S.J. Insulin receptor substrate-1-mediated enhancement of growth hormone-induced mitogen-activated protein kinase activation. Endocrinology 2000, 141:3328-3336.
4. Ji S., Frank S.J., Messina J.L. Growth hormone-induced differential desensitization of STAT5, ERK, and Akt phosphorylation. J. Biol. Chem. 2002, 277:28384-28393.
5. Zhu T., Ling L., Lobie P.E. Identification of a JAK2-independent pathway regulating growth hormone (GH)-stimulated p44/42 mitogen-activated protein kinase activity. GH activation of Ral and phospholipase D is Src-dependent. J. Biol. Chem. 2002, 277:45592-45603.
6. Jin H., Lanning N.J., Carter-Su C. JAK2, but not Src family kinases, is required for STAT5, ERK and Akt signaling in response to growth hormone in preadipocytes and hepatoma cells. Mol. Endocrinol. 2008, 22:1825-1841.
7. Bartke A. Genetic models in the study of anterior pituitary hormones. Genetic Variation in Hormone Systems 1979, 55-83. CRC Press, Florida. J.G.M. Shire (Ed.).
8. Sornson M.W., Wu W., Dasen J.S., et al. Pituitary lineage determination by the prophet of pit-1 homeodomain factor defective in Ames dwarfism. Nature 1996, 384:327-333.
9. Bartke A., Brown-Borg Life extension in the dwarf mice. Curr. Top. Dev. Biol. 2004, 63:189-225.
10. Heiman M.L., Tinsley F.C., Mattison J.A., Hauck S., Bartke A. Body composition of prolactin-, growth hormone, and thyrotropin-deficient Ames dwarf mice. Endocrine 2003, 20:149-154.
11. Villanua M.A., Szary A., Bartke A., Esquifino A.I. Changes in lymphoid organs of Ames dwarf mice after treatment with growth hormone, prolactin or ectopic pituitary transplants. J. Endocrinol. Invest. 1992, 15:587-595.
12. Chandrashekar V., Bartke A. Induction of endogenous insulin-like growth factor-I secretion alters the hypothalamic-pituitary-testicular function in growth hormone-deficient adult dwarf mice. Biol. Reprod. 1993, 48:544-551.
13. Brown-Borg H.M., Rakoczy S.G. Growth hormone administration to long-living dwarf mice alters multiple components of the antioxidative defense system. Mech. Ageing Dev. 2003, 124:1013-1024.
14. df) mice related to diminished CIS abundance. J. Endocrinol. 2005, 187:387-397.
15. Zhang Y., Guan R., Jiang J., Kopchick J.J., Black R.A., Baumann G., Frank S.J. Growth hormone (GH)-induced dimerization inhibits phorbol ester-stimulated GH receptor proteolysis. J. Biol. Chem. 2001, 276:24565-24573.
16. Bradford M.M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
17. Sharp Z.D., Bartke A. Evidence for down-regulation of phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR)-dependent translation regulatory signaling pathways in Ames dwarf mice. J. Gerontol. A. Biol. Sci. Med. Sci. 2005, 60:293-300.
18. Nicholson K.M., Anderson N.G. The protein kinase B/Akt signaling pathway in human malignancy. Cell. Signal. 2002, 14:381-395.
19. Jope R.S., Yuskaitis C.J., Beurel E. Glycogen synthase kinase-3 (GSK-3): inflammation, diseases, and therapeutics. Neurochem. Res. 2007, 32:577-595.
20. Memmott R.M., Dennis P.A. Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell. Signal. 2009, 21:656-664.
21. Bartke A. Is growth hormone deficiency a beneficial adaptation to aging? Evidence from experimental animals. Trends Endocrinol. Metab. 2003, 14:340-344.
22. Berryman D.E., Christiansen J.S., Johannsson G., Thorner M.O., Kopchick J.J. Role of the GH/IGF-1 axis in lifespan and healthspan: lessons from animal models. Growth Horm. IGF Res. 2008, 18:455-471.
23. Udy G.B., Towers R.P., Snell R.G., et al. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc. Natl. Acad. Sci. USA 1997, 94:7239-7244.
24. Teglund S., McKay C., Schuetz E., et al. STAT5a and STAT5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 1998, 93:841-850.
25. Klover P., Hennighausen L. Postnatal body growth is dependent on the transcription factors signal transducers and activators of transcription 5a/b in muscle: a role for autocrine/paracrine insulin-like growth factor I. Endocrinology 2007, 148:1489-1497.
26. Woelfle J., Billiard J., Rotwein P. Acute control of insulin-like growth factor-I gene transcription by growth hormone through STAT5b. J. Biol. Chem. 2003, 278:22696-22702.
27. Woelfle J., Rotwein P. In vivo regulation of growth hormone-stimulated gene transcription by STAT5b. Am. J. Physiol. Endocrinol. Metab. 2004, 286:E393-401.
28. González L., Curto L.M., Miquet J.G., Bartke A., Turyn D., Sotelo A.I. Differential regulation of membrane associated-growth hormone binding protein (MA-GHBP) and growth hormone receptor (GHR) expression by growth hormone (GH) in mouse liver. Growth Horm. IGF Res. 2007, 17:104-112.
29. Calò V., Migliavacca M., Bazan V., et al. STAT proteins: from normal control of cellular events to tumorigenesis. J. Cell. Physiol. 2003, 197:157-168.
30. Nishimoto S., Nishida E. MAPK signalling: ERK5 versus ERK1/2. EMBO Rep. 2006, 7:782-786.
31. Zhu T., Goh E.L.K., Graichen R., Ling L., Lobie P.E. Signal transduction via the growth hormone receptor. Cell. Signal. 2001, 13:599-616.
32. Miquet J.G., González L., Matos M.N., et al. Transgenic mice overexpressing GH exhibit hepatic upregulation of GH-signaling mediators involved in cell proliferation. J. Endocrinol. 2008, 198:317-330.
33. Dominici F.P., Argentino D., Hauck S., Bartke A., Turyn D. Increased Insulin sensitivity and up-regulation of insulin receptor insulin receptor, substrated (IRS)-1 and IRS-2 in liver of Ames dwarf mice. J. Endocrinol. 2002, 173:81-94.
34. Dominici F.P., Argentino D.P., Bartke A., Turyn D. The dwarf mutation decreases high dose insulin responses in skeletal muscle, the opposite of effects in liver. Mech. Ageing Dev. 2003, 124:819-827.
35. Hayashi A.A., Proud C.G. The rapid activation of protein synthesis by growth hormone requires signaling through mTOR. Am. J. Physiol. Endocrinol. Metab. 2007, 292:E1647-E1655.
36. Wilson E.M., Rotwein P. Selective control of skeletal muscle differentiation by Akt1. J. Biol. Chem. 2007, 282:5106-5110.
37. Frost R.A., Lang C.H. Protein kinase B/Akt: a nexus of growth factor and cytokine signaling in determining muscle mass. J. Appl. Physiol. 2007, 103:378-387.
38. Hsieh C.C., Papaconstantinou J. Akt/PKB and p38 MAPK signaling, translation initiation and longevity Snell dwarf mouse livers. Mech. Ageing Dev. 2004, 125:785-798.
39. Thirone A.C., Carvalho C.R., Saad M.J. Growth hormone stimulates the tyrosine kinase activity of JAK2 and induces tyrosine phosphorylation of insulin receptor substrates and Shc in rat tissues. Endocrinology 1999, 140:55-62.
40. Chow J.C., Ling P.Q., Qu Z., et al. but not insulin receptor substrate-1 or SHC proteins in liver and skeletal muscle of normal rats in vivo. Endocrinology 1996, 137:2880-2886.
41. Sadowski C.L., Wheeler T.T., Wang L.H., Sadowski H.B. GH regulation of IGF-I and suppressor of cytokine signaling gene expression in C2C12 skeletal muscle cells. Endocrinology 2001, 142:3890-3900.
42. Frost R.A., Nystrom G.J., Lang C.H. Regulation of IGF-I mRNA and signal transducers and activators of transcription-3 and -5 (STAT-3 and -5) by GH in C2C12 myoblasts. Endocrinology 2002, 143:492-503.
43. Jørgensen J.O., Jessen N., Pedersen S.B., et al. GH receptor signaling in skeletal muscle and adipose tissue in human subjects following exposure to an intravenous GH bolus. Am. J. Physiol. Endocrinol. Metab. 2006, 291:E899-905.
44. Flores-Morales A., Greenhalgh C.J., Norstedt G., Rico-Bautista E. Negative regulation of growth hormone receptor signaling. Mol. Endocrinol. 2006, 20:241-253.
45. Landsman T., Waxman D.J. Role of the cytokine-induced SH2 domain-containing protein CIS in growth hormone receptor internalization. J. Biol. Chem. 2005, 280:37471-37480.
46. Uyttendaele I., Lemmens I., Verhee A., De Smet A.S., Vandekerckhove J., Lavens D., Peelman F., Tavernier J. Mammalian protein-Protein interaction trap (MAPPIT) analysis of STAT5, CIS, and SOCS2 interactions with the growth hormone receptor. Mol. Endocrinol. 2007, 21:2821-2831.
47. Orian J.M., Tamakoshi K., Mackay I.R., Brandon M.R. New murine model for hepatocellular carcinoma: transgenic mice expressing metallothionein-ovine growth hormone fusion gene. J. Natl. Cancer Inst. 1990, 82:393-398.
48. Snibson K.J. Hepatocellular kinetics and the expression of growth hormone (GH) in the livers and liver tumours of GH-transgenic mice. Tissue Cell 2002, 34:88-97.
49. Ikeno Y., Bronson R.T., Hubbard G.B., Lee S., Bartke A. Delayed occurrence of fatal neoplastic in Ames dwarf mice: correlation to extended longevity. J. Gerontol. A. Biol. Sci. Med. Sci. 2003, 58:291-296.
50. Alderman J.M., Flurkey K., Brooks N.L., et al. Neuroendocrine inhibition of glucose production and resistance to cancer in dwarf mice. Exp. Gerontol. 2009, 44:26-33.